Vaxart, Inc. Form 8-K (June 22, 2022)

Summary

Form 8-K for an event dated June 22, 2022, filed by Vaxart, Inc. Under Item 8.01, Other Events, the report states that on June 22, 2022 the company conducted a live question-and-answer session via webcast with investors, giving an overview of the company's oral vaccine programs and discussing the proposals for the annual meeting of stockholders, now set for July 6, 2022 after the adjournment. A copy of the investor questions and answers is attached as Exhibit 99.1. Andrei Floroiu, Chief Executive Officer, signed June 28, 2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 22, 2022

Vaxart, Inc.

(Exact name of registrant as specified in its charter)

Delaware | 001-35285 | 59-1212264
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.)
170 Harbor Way, Suite 300 , South San Francisco , California | 94080
(Address of principal executive offices) | (Zip Code)

Registrant ’ s telephone number, including area code: ( 650 ) 550-3500

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading symbol | Name of each exchange on which registered
Common Stock , $0.0001 par value | VXRT | The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On June 22, 2022, Vaxart, Inc. (the “Company”) held a live question-and-answer session via webcast with investors to provide an overview of the Company’s oral vaccine programs and to discuss the proposals being submitted at the Company’s annual meeting of stockholders, which is now being held on July 6, 2022, following its adjournment.

A copy of the Company’s investor questions and answers is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Copy of investor questions and answers .

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Vaxart, Inc.
Dated: June 28, 2022
By: | /s/ Andrei Floroiu
Andrei Floroiu
Chief Executive Officer

File and source

File

SEC_VXRT_8-K_filed2022-06-28_0001437749-22-016094.htm

Size

26,583 bytes

SHA-256

7bac5ae4909cd1f1691f61877a327851933b2cfbafcfa67c07b32c7aa219161d

Our copy

SEC_VXRT_8-K_filed2022-06-28_0001437749-22-016094.htm

Original

www.sec.gov